Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat, delay, or stop the disease is paramount. While current therapies used to treat AD are generically available in Europe, the next five years look set to bring several premium-priced new brands addressing the cognitive as well as the behavioral symptoms of AD. This research examines the current impact of payer policy on prescribing and probes how neurologists and cost-conscious European payers will react to novel agents that, while innovative, will drive up healthcare costs considerably.

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Key Updates
      • November 2017
      • August 2017
      • May 2017
    • Market Access Overview
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for Alzheimer's Disease Therapies in the EU5
    • Successes and Stumbles
      • Successes Among Alzheimer's Disease Therapies in the EU5
      • Stumbles Among Alzheimer's Disease Therapies in the EU5
    • Key Stakeholders in the Road to Market Access
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
    • Key Market Access Roadblocks
    • Reimbursement Dynamics
      • France
        • France: Crucial HTA Criteria
        • France: HTA Review Details
        • France: Reimbursement Regulations and Prescribing Parameters
        • France: Key Takeaways
      • Germany
        • Germany: Crucial HTA Criteria
        • Germany: HTA Review Details
        • Germany: Reimbursement Regulations and Prescribing Parameters
        • Germany: Key Takeaways
      • Italy
        • Italy: Crucial HTA Criteria
        • Italy: Reimbursement Regulations and Prescribing Parameters
        • Italy: Key Takeaways
      • Spain
        • Spain: Crucial HTA Criteria
        • Spain: P&R Drivers and Key HTA Considerations
        • Spain: Reimbursement Regulations and Prescribing Parameters
        • Spain: Key Takeaways
      • United Kingdom
        • United Kingdom: Crucial HTA Criteria
        • United Kingdom: Reimbursement Regulations and Prescribing Parameters
        • United Kingdom: Key Takeaways
    • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
      • Prescriber Preferences for Alzheimer's Disease
      • Impact of Payer Policy on Prescribing for Alzheimer's Disease
        • Overall Impact of EU5 Payer Policy on Prescribing for Alzheimer's Disease
        • Impact of Country-Specific Payer Policy on Prescribing for Alzheimer's Disease
      • Top Prescribing Drivers in Alzheimer's Disease
    • Market Access Landscape for Emerging Therapies
      • Likely Impact of Emerging Therapies for Alzheimer's Disease
        • Likely Impact of Emerging Disease-Modifying Therapies for Alzheimer's Disease
        • Likely Impact of Emerging Symptomatic Therapies for Alzheimer's Disease
        • Likely Impact of Emerging Behavioral Therapies for Alzheimer's Disease
      • Market Access Challenges for Emerging Alzheimer's Disease Therapies
      • Payer Opinion on Emerging Therapies for Alzheimer's Disease
    • Methodology
      • Primary Research Design
      • Physician Demographics and Practice Setting
    • Appendix
      • Country-Specific Reimbursement Background Details
        • France: Reimbursement Background
        • Germany: Reimbursement Background
        • Italy: Reimbursement Background
        • Spain: Reimbursement Background
        • United Kingdom: Reimbursement Background
      • Key Current and Emerging Therapies for Alzheimer's Disease
        • Emerging Therapy Profiles
        • Lundbeck/Otsuka's Brexpiprazole
      • Physician Survey Data

Author(s): Tamara Blutstein, PhD; Anna Reyes, MSc

Tamara Blutstein is a Senior Business Insights Analyst on the Central Nervous System, Pain, and Ophthalmology team. She is responsible for analyzing and forecasting pharmaceutical markets, primarily in Neurology indications, with specific expertise in Alzheimer’s disease, Parkinson’s disease, and ischemic stroke. Prior to joining the company, Tamara was a postdoctoral fellow at Tufts University School of Medicine, where she studied the role of gliotransmission in the regulation of sleep and sleep homeostasis. She earned a in neuroscience from the University of Maryland School of Medicine where she conducted research on the role of gonadal hormones in modulating neuronal-glial communication. She holds a in neuroscience from Drew University.

Anna Reyes is an analyst on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Anna’s specific focus is on all aspects of market access in the EU5, as well as in select LatAm countries. Anna holds a bachelor’s degree from the University Rovira i Virgili and a master’s degree in bioengineering from IQS Barcelona.


Related Reports

Alzheimer's Disease | Landscape & Forecast | Disease Landscape & Forecast

The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving am...

View Details

Alzheimer's Disease | Special Topics | Detailed, Expanded Analysis - Special Topics (US & EU)

Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to i...

View Details

Alzheimer's Disease | Unmet Need | Detailed, Expanded Analysis (US&EU) Early Alzheimer's Disease

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (

View Details

Alzheimer's Disease | Access & Reimbursement | Detailed, Expanded Analysis (US)

No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of th...

View Details